Skip to main content
SpringerPlus

Table 7 Multivariate models corresponding to progression-free survival and overall survival

From: Pretreatment levels of the serum biomarkers CEA, CYFRA 21–1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients

 

Progression-free survival

Overall survival

 

HR

95% CI

p a

HR

95% CI

p a

sEGFR

      

<56.87

1.000

  

1.000

  

≥56.87

0.406

0.151 – 1.089

0.073

0.271

0.096 – 0.760

0.013

Mutational status

      

Wild type

1.000

  

1.000

  

EGFR Mutated

0.716

0.218 – 2.354

0.583

0.726

0.196 – 2.696

0.633

Toxicity

      

No

1.000

  

1.000

  

Yes

0.201

0.047 – 0.854

0.030

0.088

0.018 – 0.425

0.002

  1. Abbreviations: HR Hazard Ratio, CI Confidence interval.
  2. aWald test is used to calculate HR.
Back to article page